艾伦比克制药获得FDA批准, 价值2820万美元的Diltiazem药囊用于治疗高血压. Alembic Pharma receives FDA approval for generic Diltiazem capsules, worth $28.2 million, to treat hypertension.

Alembic制药有限公司已获得美国林业发展局对其用于治疗高血压的通用Diltiazem氢氯化物延长释放胶囊的最后批准。 Alembic Pharmaceuticals Ltd has received final approval from the US FDA for its generic Diltiazem Hydrochloride extended-release capsules, used to treat hypertension. 这些胶囊以120毫克、180毫克和240毫克强度提供,在治疗上相当于Allergan的Dilacor XR。 The capsules, available in 120 mg, 180 mg, and 240 mg strengths, are therapeutically equivalent to Allergan's Dilacor XR. 这些胶囊的市场规模估计在2024年6月终了的一年中为2 820万美元。 The estimated market size for these capsules is $28.2 million for the year ending June 2024. 现在Alembic已经获得了FDA的217个ANDA批准. Alembic now has a total of 217 ANDA approvals from the FDA.